Biogen Inc.

NasdaqGS:BIIB Lagerbericht

Marktkapitalisierung: US$27.6b

Biogen Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

Biogen wird ein jährliches Gewinn- und Umsatzwachstum von 13.9% bzw. 2.4% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 14.4% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 12.5% betragen.

Wichtige Informationen

13.9%

Wachstumsrate der Gewinne

14.43%

EPS-Wachstumsrate

Biotechs Gewinnwachstum24.1%
Wachstumsrate der Einnahmen2.4%
Zukünftige Eigenkapitalrendite12.51%
Analystenabdeckung

Good

Zuletzt aktualisiert04 May 2026

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

BIIB: 2026 Readouts In Neurology And Immunology Will Drive Upside Potential

Analysts have lifted Biogen's fair value estimate by about $18 to $273.20 as they factor in updated revenue growth assumptions, a higher future P/E, and recent price target revisions across the Street. Analyst Commentary Recent Street research around Biogen has leaned constructive, with a cluster of fresh price target adjustments and several rating upgrades pointing to improving sentiment on execution and long term growth potential.

BIIB: 2026 Trial Outcomes Will Likely Undermine Recent Acquisition Optimism

Analysts made a slight upward adjustment to Biogen's fair value estimate to about $151, reflecting a blend of higher and lower price target revisions related to recent acquisition activity, pipeline updates, and shifting views on its long term earnings profile. Analyst Commentary Recent Street research around Biogen has been active, with a mix of higher and lower price targets clustered around the company’s acquisition activity, pipeline readouts, and changing expectations for longer term earnings power.

Revisiting Eisai And Biogen's Leqembi Data For Alzheimer's Disease

Apr 06

BIIB: 2026 Clinical Outcomes Will Likely Challenge Recent Neuroscience Optimism

The analyst price target for Biogen has been adjusted slightly to $150. This reflects recent model updates that incorporate a modestly higher discount rate, slightly lower revenue growth assumptions, a small uptick in expected profit margins, and Street research focusing on price target changes and evolving views on the company's pipeline and neurology portfolio.

Biogen Inc. (BIIB): The "Post-MS" Pivot and the Alzheimer’s Momentum

Biogen Inc. (BIIB) is navigating a high-stakes transition year in 2026, closing the March 31, 2026, session at $178.98 USD on the NASDAQ.

BIIB: 2026 Clinical Readouts Will Likely Undermine Recent Pipeline Optimism

Analysts have nudged Biogen's fair value estimate higher to $151.48 from $147.47, reflecting a series of recent price target increases across the Street and ongoing reassessments of the company's pipeline and commercial outlook. Analyst Commentary Recent Street research around Biogen points to a mixed setup, with several firms adjusting price targets and ratings as they reassess the pipeline, commercial execution, and sector positioning.

BIIB: 2026 Clinical Readouts And Easing Policy Risks Will Drive Upside

The analyst fair value estimate for Biogen has increased by about $16 to $205.67 as analysts factor in recent price target revisions and updated views on the pipeline and commercial outlook. Analyst Commentary Recent research updates on Biogen cluster around revisions to price targets, refreshed models on the pipeline, and differing expectations for execution in 2026 and beyond.

BIIB: 2026 Clinical Readouts Will Likely Expose Pipeline Execution Risk

The analyst price target for Biogen has been raised from $143.00 to $147.47. Analysts point to a stronger profit margin outlook and updated pipeline and commercial assumptions as key drivers of the change.

There May Be Reason For Hope In Biogen's (NASDAQ:BIIB) Disappointing Earnings

Feb 13
There May Be Reason For Hope In Biogen's (NASDAQ:BIIB) Disappointing Earnings

BIIB: 2026 Clinical Readouts And Pipeline Execution Will Drive Upside Potential

Analysts have nudged their price targets on Biogen higher, with our fair value estimate rising to about $255.45 from $247.88 as they update models for revenue growth, margins, and a modestly richer future P/E multiple following a series of mixed but generally upward target revisions across the Street. Analyst Commentary Recent research on Biogen has been mixed, but the pricing and modeling changes skew toward a constructive tone.

BIIB: 2026 Clinical Readouts Will Test Lofty Pipeline Expectations

Analysts have raised their Biogen fair value estimate from $128.00 to $143.00, citing refreshed models and higher Street price targets as they incorporate updated views on the pipeline, sector conditions, and 2026 catalysts. Analyst Commentary Street research around Biogen points to a generally more constructive view on the shares, with several firms lifting price targets into a range between about $180 and $225.

BIIB: Easing Policy Shifts And 2026 Pipeline Readouts Will Shape Outlook

Narrative Update: Biogen (BIIB) Biogen's fair value estimate has moved from about $181 to around $190 as analysts lift price targets into the $180 to $225 range and highlight updated models, slightly better margin and growth assumptions, and potential pipeline and sector catalysts through 2026. Analyst Commentary Recent research updates on Biogen cluster around a tighter valuation band in the high US$100s to low US$200s, with most firms revisiting their models and assumptions for 2025 to 2026.

BIIB: Easing Policy Overhangs And Alzheimer’s Data Will Shape Risk Reward Balance

Analysts have modestly raised their price target on Biogen, now implying upside in line with a slightly higher fair value of approximately $181, citing easing policy overhangs and a partial rerating of large-cap biopharma as investor focus shifts back to fundamentals. Analyst Commentary Street research on Biogen has turned incrementally more constructive, with several firms lifting price targets as macro and policy risks appear less threatening to the sector.

BIIB: Policy Environment And Late-Stage Pipeline Will Shape Risk And Reward Ahead

Analysts have modestly increased their price target for Biogen, lifting fair value by about $1 to roughly $179 per share. They cite easing policy overhangs, growing confidence in 2025 to 2026 fundamentals, and potential upside from Leqembi and the broader late stage pipeline.

BIIB: Policy Shifts And Drug Pipeline Progress Will Influence Risk And Reward Ahead

Biogen's analyst price target has been increased modestly, with the fair value estimate rising from $176.72 to $178.07. Analysts point to easing policy headwinds and renewed focus on company fundamentals amid recent sector re-ratings.

BIIB: Pipeline And Policy Developments Will Shape Risk And Reward Into 2025

Analysts have raised their price target for Biogen by approximately $4 to $176.72, citing improving sector fundamentals, easing policy risks, and a favorable risk/reward outlook as reasons for the adjustment. Analyst Commentary Recent street research on Biogen provides insight into both the optimistic and cautious perspectives that currently shape the stock's outlook.

Easing Policy Risks And New Therapy Launches Will Drive Shares Higher

Analysts have slightly raised their price target for Biogen to $172.55 from $172.34, reflecting modestly improved revenue growth expectations and an easing policy backdrop in the biotech sector. Analyst Commentary Recent street research reveals a spectrum of opinions around Biogen, highlighted by both bullish and bearish analyst actions.

Expanding Global Healthcare And Diagnostics Infrastructure Will Drive Future Growth

Analysts have slightly lifted their price targets for Biogen, with the updated fair value estimate rising from $170.03 to $172.34. This reflects improved profit margin expectations and easing industry headwinds cited in recent research updates.

Expanding Global Healthcare And Diagnostics Infrastructure Will Drive Future Growth

Biogen's modestly reduced consensus price target reflects a balanced analyst view, with optimism around strong Q2 performance, pipeline progress, and portfolio refocusing offset by lingering regulatory overhangs and a muted near-term growth outlook, resulting in a slight decrease in fair value from $171.96 to $170.03. Analyst Commentary Bullish analysts cite strong Q2 performance, particularly from Leqembi and the MS franchise, as well as solid sales across other programs as drivers for raised price targets.

Expanding Global Healthcare And Diagnostics Infrastructure Will Drive Future Growth

Biogen’s consensus price target was modestly raised as analysts highlighted strong Q2 performance, advancements in its neuro portfolio and pipeline, and ongoing portfolio refocusing, offsetting medium-term growth concerns and regulatory risks; the new fair value is now $171.96. Analyst Commentary Bullish analysts highlight strong Q2 performance, particularly in Leqembi and the MS franchise, combined with solid sales across other programs, supporting upward revisions in price targets.

Biogen (NASDAQ:BIIB) Seems To Use Debt Quite Sensibly

Jun 17
Biogen (NASDAQ:BIIB) Seems To Use Debt Quite Sensibly

Biogen: Is This A Value Trap, Or Is The Great Turnaround Imminent?

Apr 25

Biogen: Balancing Risks And Opportunities

Mar 27

Biogen Q4 Earnings Review: Why I'm Calling Time On This 'Powder Puff' Pharma

Feb 15

Gewinn- und Umsatzwachstumsprognosen

NasdaqGS:BIIB - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
DatumUmsatzGewinneFreier CashflowBargeld aus operativen TätigkeitenDurchschn. Anz. Analysten
12/31/202810,6082,1342,4063,32217
12/31/202710,3171,9292,5742,63622
12/31/202610,0121,1402,6971,84222
3/31/20269,9371,3722,3162,591N/A
12/31/20259,8911,2931,9692,205N/A
9/30/202510,0661,6092,2622,454N/A
6/30/20259,9971,5311,8322,117N/A
3/31/20259,8161,4792,3842,582N/A
12/31/20249,6761,6322,6042,876N/A
9/30/20249,6081,6151,8572,127N/A
6/30/20249,6721,1591,5711,784N/A
3/31/20249,6631,1671,2841,645N/A
12/31/20239,8361,1611,2361,547N/A
9/30/20239,9931,4621,0261,360N/A
6/30/20239,9722,6651,1231,428N/A
3/31/202310,1053,1311,4211,678N/A
12/31/202210,1733,0471,1411,384N/A
9/30/202210,3632,8652,1732,398N/A
6/30/202210,6342,0592,3152,542N/A
3/31/202210,8201,4502,7733,033N/A
12/31/202110,9821,5563,3453,640N/A
9/30/202111,1011,5462,1072,435N/A
6/30/202111,6981,9182,4612,810N/A
3/31/202112,6043,0123,1493,532N/A
12/31/202013,4454,0013,6784,230N/A
9/30/202014,2635,0825,8416,557N/A
6/30/202014,4875,9276,3497,071N/A
3/31/202014,4225,8796,2827,086N/A
12/31/201914,3785,889N/A7,079N/A
9/30/201914,2335,396N/A7,014N/A
6/30/201914,0725,294N/A7,055N/A
3/31/201913,8124,667N/A6,190N/A
12/31/201813,4534,431N/A6,188N/A
9/30/201813,2343,187N/A5,811N/A
6/30/201812,8722,968N/A5,703N/A
3/31/201812,5942,964N/A5,773N/A
12/31/201712,2742,539N/A4,551N/A
9/30/201711,8393,486N/A4,615N/A
6/30/201711,7173,293N/A3,978N/A
3/31/201711,5333,480N/A3,807N/A
12/31/201611,4493,703N/A4,587N/A
9/30/201611,4163,885N/A4,046N/A
6/30/201611,2383,818N/A3,950N/A
3/31/201610,9363,695N/A3,999N/A
12/31/201510,7643,547N/A3,919N/A
9/30/201510,5653,599N/A3,609N/A
6/30/201510,2993,490N/A3,627N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: BIIBDas prognostizierte Gewinnwachstum (13.9% pro Jahr) liegt über der Sparquote (3.5%).

Ertrag vs. Markt: BIIBDie Erträge des Unternehmens (13.9% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (16.1% pro Jahr).

Hohe Wachstumserträge: BIIBDie Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.

Einnahmen vs. Markt: BIIBDie Einnahmen des Unternehmens (2.4% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (11.3% pro Jahr).

Hohe Wachstumseinnahmen: BIIBDie Einnahmen des Unternehmens (2.4% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: BIIBDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (12.5%).

Wachstumsunternehmen entdecken

7D

1Y

7D

1Y

7D

1Y

Unternehmensanalyse und Finanzdaten Status

DatenZuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse2026/05/05 18:51
Aktienkurs zum Tagesende2026/05/05 00:00
Gewinne2026/03/31
Jährliche Einnahmen2025/12/31

Datenquellen

Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.

PaketDatenZeitrahmenBeispiel US-Quelle *
Finanzdaten des Unternehmens10 Jahre
  • Gewinn- und Verlustrechnung
  • Kapitalflussrechnung
  • Bilanz
Konsensschätzungen der Analysten+3 Jahre
  • Finanzielle Vorausschau
  • Kursziele der Analysten
Marktpreise30 Jahre
  • Aktienkurse
  • Dividenden, Splits und Aktionen
Eigentümerschaft10 Jahre
  • Top-Aktionäre
  • Insiderhandel
Verwaltung10 Jahre
  • Das Führungsteam
  • Direktorium
Wichtige Entwicklungen10 Jahre
  • Ankündigungen des Unternehmens

* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.

Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.

Analysemodell und Schneeflocke

Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.

Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.

Metriken für Industrie und Sektor

Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.

Analysten-Quellen

Biogen Inc. wird von 58 Analysten beobachtet. 22 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.

AnalystEinrichtung
David ToungArgus Research Company
Brian SkorneyBaird
Emily FieldBarclays